In a Bloomberg survey based on the recommendations of 19 brokerage companies, Intuitive Surgical (ISRG) was given “buy” rating by ~68.4% of analysts surveyed. About 26.3% issued “hold” recommendations, and only one firm (5.3% of firms surveyed) issued a “sell” recommendation on the stock.
Receive e-mail alerts for new research on ISRG:
Interested in ISRG?
Don’t miss the next report.
The table above lists the 12 brokerage firms that provided target prices for Intuitive Surgical for the next 12 months. The consensus 12-month target price is $763.5, which amounts to an ~12% return potential, as compared to Intuitive Surgical’s price of $681.8 on October 20, 2016.
As of October 19, 2016, Northland Securities gave Intuitive Surgical a one-year target price of $600—the lowest target price among analysts—which implies a -12% return over the next 12 months.
Among the large investment banks, Morgan Stanley gave Intuitive Surgical a one-year target price of $800, which implies a ~17.3% return potential over the next 12 months.
Leerink Partners gave the stock its highest one-year target price of $810, which implies a return of ~18.8%.
Peers TransEnterix (TRXC), Medtronic (MDT), and Stryker (SYK) have average broker target prices of $3.3, $94.7, and $127.2, respectively. These figures imply returns of 80.8%, 12.8%, and 11.1%, respectively, during the next 12 months.
Remember, investors can get diversified exposure to Intuitive Surgical by investing in the Vanguard Growth ETF (VUG). VUG has 0.29% of its total holdings in ISRG.